Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Company and Kissei Pharmaceutical have announced that they will launch Urief tablet 2mg and Urief tablet 4mg on February 5, 2009 in Japan. Urief is used for the treatment of dysuria associated with benign prostatic hyperplasia.
Subscribe to our email newsletter
The Urief tablet is a new formulation of Urief capsule 2mg and Urief capsule 4mg, which were jointly marketed by Daiichi Sankyo and Kissei in Japan since 2006. Urief was originally discovered by Kissei and was co-developed by Daiichi Sankyo and Kissei.
The tablet reportedly makes it easier for elderly patients and patients with dysphagia to swallow compared with the capsule. Additionally, Urief tablet 4mg has a cleavage line to allow for dosage adjustment and thus improves the convenience for patients and medical professionals, said Daiichi.
By selectively blocking alpha 1A-adrenoceptors that primarily exist in the prostate gland, Urief reportedly removes the tension of the prostate gland to improve urethral resistance, thereby improving dysuria associated with benign prostatic hyperplasia. Compared with existing drugs, Urief offers faster onset and improves symptoms such as difficulty of urination, frequent urination and urinary incontinence, the company added.